|
業務類別
|
Drug Manufacturers - Specialty & Generic |
|
業務概覽
|
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States. |
| 公司地址
| 30 Technology Drive, Warren, NJ, USA, 07059 |
| 電話號碼
| +1 908 941-1900 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.aquestive.com |
| 員工數量
| 147 |
| Mr. Thomas A. Zalewski |
Chief Legal Officer and Chief Compliance Officer |
-- |
20/03/2026 |
| Ms. Sherry Korczynski |
Chief Commercial Officer |
-- |
24/04/2026 |
| Mr. Daniel Barber |
Director, Chief Executive Officer and President |
美元 659.89K |
24/04/2026 |
| Mr. Peter Boyd |
Chief People Officer |
-- |
24/04/2026 |
| Mr. Matthew W. Davis, R.Ph. |
Chief Development Officer |
-- |
24/04/2026 |
| Ms. Lori J. Braender |
Corporate Secretary |
美元 457.96K |
20/03/2026 |
| Mr. Matthew J. Greenhawt, M.D. |
Chief Medical Officer |
-- |
24/04/2026 |
| Dr. Melina T. Cioffi, Pharm.D. |
Senior Vice President, Regulatory Affairs |
-- |
24/04/2026 |
| Ms. Cassie Jung |
Chief Operating Officer |
-- |
24/04/2026 |
| Mr. A. Ernest Toth, Jr |
Chief Financial Officer and Principal Accounting Officer |
美元 442.60K |
24/04/2026 |
|
|
| Dr. Gregory B. Brown,M.D. |
Chairman of the Board |
24/04/2026 |
| Dr. Marco Taglietti,M.D. |
Independent Director |
24/04/2026 |
| Dr. Julie Krop, M.D. |
Independent Director |
24/04/2026 |
| Mr. Timothy E. Morris |
Independent Director |
24/04/2026 |
| Mr. Daniel Barber |
Director, Chief Executive Officer and President |
24/04/2026 |
| Mr. John S. Cochran |
Vice Chairman of the Board |
24/04/2026 |
| Ms. Abigail L. Jenkins, B.A.,M.S. |
Independent Director |
24/04/2026 |
|
|
|
|
